TY - JOUR
T1 - Cost-effectiveness of a novel AI technology to quantify coronary inflammation and cardiovascular risk in patients undergoing routine coronary computed tomography angiography
AU - Tsiachristas, Apostolos
AU - Chan, Kenneth
AU - Wahome, Elizabeth
AU - Kearns, Ben
AU - Patel, Parijat
AU - Lyasheva, Maria
AU - Syed, Nigar
AU - Fry, Sam
AU - Halborg, Thomas
AU - West, Henry
AU - Nicol, Edward
AU - Adlam, David
AU - Modi, Bhavik
AU - Kardos, Attila
AU - Greenwood, John P.
AU - Sabharwal, Nikant
AU - De Maria, Giovanni Luigi
AU - Munir, Shahzad
AU - Mcalindon, Elisa
AU - Sohan, Yogesh
AU - Tomlins, Pete
AU - Siddique, Muhammad
AU - Shirodaria, Cheerag
AU - Blankstein, Ron
AU - Desai, Milind
AU - Neubauer, Stefan
AU - Channon, Keith M.
AU - Deanfield, John
AU - Akehurst, Ron
AU - Antoniades, Charalambos
AU - on behalf of the ORFAN Consortium
AU - Thomas, Sheena
AU - Denton, Jon
AU - Farrall, Robyn
AU - Taylor, Caroline
AU - Qin, Wendy
AU - Kasongo, Mary
AU - Ledesma, Chrisha
AU - Darby, Damaris
AU - Santos, Bruno Silva
AU - Antonopoulos, Alexios S.
AU - Mavrogiannis, Michail C.
AU - Kelion, Andrew
AU - Anthony, Susan
AU - Banning, Adrian
AU - Xie, Cheng
AU - Kotronias, Rafail A.
AU - Kingham, Lucy
AU - Kharbanda, Rajesh K.
AU - Mathers, Chris
AU - Mittal, Tarun K.
AU - Rose, Anne
AU - Hudson, George
AU - Bajaj, Amrita
AU - Das, Intrajeet
AU - Deshpande, Aparna
AU - Rao, Praveen
AU - Lawday, Dan
AU - Pugliese, Francesca
AU - Petersen, Steffen E.
AU - Mirsadraee, Saeed
AU - Screaton, Nicholas
AU - Rodrigues, Jonathan
AU - Hudson, Benjamin
AU - Graby, John
AU - Berry, Colin
AU - Marwan, Mohamed
AU - Maurovich-Horvat, Pál
AU - He, Guo Wei
AU - Lin, Wen Hua
AU - Fan, Li Juan
AU - Takahashi, Naohiko
AU - Kondo, Hidekazu
AU - Dai, Neng
AU - Ge, Junbo
AU - Koo, Bon Kwon
AU - Guglielmo, Marco
AU - Pontone, Gianluca
AU - Huck, Daniel
AU - Benedek, Theodora
AU - Rajani, Ronak
AU - Vilic, Dijana
AU - Aljazzaf, Haleema
AU - Mun, Mak S.
AU - Benedetti, Giulia
AU - Preston, Rebecca L.
AU - Raisi-Estabragh, Zahra
AU - Connolly, Derek L.
AU - Sharma, Vinoda
AU - Grenfell, Rebecca
AU - Bradlow, William
AU - Schmitt, Matthias
AU - Serfaty, Fabiano
AU - Gottlieb, Ilan
AU - Neves, Mario F.T.
AU - Newby, David E.
AU - Dweck, Marc R.
AU - Gersh, Bernard J.
AU - Hatem, Stéphane
AU - Redheuil, Alban
AU - Benetos, Georgios
AU - Beer, Meinrad
AU - Rodriguez-Granillo, Gastón A.
AU - Selvanayagam, Joseph
AU - Lopez-Jimenez, Francisco
AU - De Bosscher, Ruben
AU - Tavildari, Alain
AU - Figtree, Gemma
AU - Danad, Ibrahim
AU - Shantouf, Ronney
AU - Kietselaer, Bas
AU - Tousoulis, Dimitris
AU - Dangas, George
AU - Mehta, Nehal N.
AU - Kotanidis, Christos
AU - Kunadian, Vijay
AU - Fairbairn, Timothy A.
PY - 2025/6
Y1 - 2025/6
N2 - Aims Coronary computed tomography angiography (CCTA) is a first-line investigation for chest pain in patients with suspected obstructive coronary artery disease (CAD). However, many acute cardiac events occur in the absence of obstructive CAD. We assessed the lifetime cost-effectiveness of integrating a novel artificial intelligence-enhanced image analysis algorithm (AI-Risk) that stratifies the risk of cardiac events by quantifying coronary inflammation, combined with the extent of coronary artery plaque and clinical risk factors, by analysing images from routine CCTA. Methods and results A hybrid decision-tree with population cohort Markov model was developed from 3393 consecutive patients who underwent routine CCTA for suspected obstructive CAD and followed up for major adverse cardiac events over a median (interquartile range) of 7.7(6.4-9.1) years. In a prospective real-world evaluation survey of 744 consecutive patients undergoing CCTA for chest pain investigation, the availability of AI-Risk assessment led to treatment initiation or intensification in 45% of patients. In a further prospective study of 1214 consecutive patients with extensive guidelines recommended cardiovascular risk profiling, AI-Risk stratification led to treatment initiation or intensification in 39% of patients beyond the current clinical guideline recommendations. Treatment guided by AI-Risk modelled over a lifetime horizon could lead to fewer cardiac events (relative reductions of 11%, 4%, 4%, and 12% for myocardial infarction, ischaemic stroke, heart failure, and cardiac death, respectively). Implementing AI-Risk Classification in routine interpretation of CCTA is highly likely to be cost-effective (incremental cost-effectiveness ratio £1371-3244), both in scenarios of current guideline compliance, or when applied only to patients without obstructive CAD. Conclusions Compared with standard care, the addition of AI-Risk assessment in routine CCTA interpretation is cost-effective, by refining risk-guided medical management.
AB - Aims Coronary computed tomography angiography (CCTA) is a first-line investigation for chest pain in patients with suspected obstructive coronary artery disease (CAD). However, many acute cardiac events occur in the absence of obstructive CAD. We assessed the lifetime cost-effectiveness of integrating a novel artificial intelligence-enhanced image analysis algorithm (AI-Risk) that stratifies the risk of cardiac events by quantifying coronary inflammation, combined with the extent of coronary artery plaque and clinical risk factors, by analysing images from routine CCTA. Methods and results A hybrid decision-tree with population cohort Markov model was developed from 3393 consecutive patients who underwent routine CCTA for suspected obstructive CAD and followed up for major adverse cardiac events over a median (interquartile range) of 7.7(6.4-9.1) years. In a prospective real-world evaluation survey of 744 consecutive patients undergoing CCTA for chest pain investigation, the availability of AI-Risk assessment led to treatment initiation or intensification in 45% of patients. In a further prospective study of 1214 consecutive patients with extensive guidelines recommended cardiovascular risk profiling, AI-Risk stratification led to treatment initiation or intensification in 39% of patients beyond the current clinical guideline recommendations. Treatment guided by AI-Risk modelled over a lifetime horizon could lead to fewer cardiac events (relative reductions of 11%, 4%, 4%, and 12% for myocardial infarction, ischaemic stroke, heart failure, and cardiac death, respectively). Implementing AI-Risk Classification in routine interpretation of CCTA is highly likely to be cost-effective (incremental cost-effectiveness ratio £1371-3244), both in scenarios of current guideline compliance, or when applied only to patients without obstructive CAD. Conclusions Compared with standard care, the addition of AI-Risk assessment in routine CCTA interpretation is cost-effective, by refining risk-guided medical management.
KW - Coronary artery disease
KW - Coronary CT angiography
KW - Cost-effectiveness analysis
KW - Inflammation
UR - http://www.scopus.com/inward/record.url?scp=105009649124&partnerID=8YFLogxK
U2 - 10.1093/ehjqcco/qcae085
DO - 10.1093/ehjqcco/qcae085
M3 - Article
C2 - 39341792
AN - SCOPUS:105009649124
SN - 2058-5225
VL - 11
SP - 434
EP - 444
JO - European Heart Journal - Quality of Care and Clinical Outcomes
JF - European Heart Journal - Quality of Care and Clinical Outcomes
IS - 4
ER -